On March 3, 2014 Roche announced that an independent data monitoring committee has recommended that the Phase III METLung study be stopped due to a lack of clinically meaningful efficacy (Press release Hoffmann-La Roche, MAR 3, 2014, View Source [SID:1234500215]).
The study evaluated if onartuzumab (MetMab) in combination with Tarceva (erlotinib) helped patients with previously treated, advanced non-small cell lung cancer (NSCLC) whose tumors were identified as MET-positive live longer compared to Tarceva alone. Overall adverse event rates were generally similar between the two groups. Data will be submitted for presentation at a forthcoming medical meeting.
Roche is evaluating the implications of the METLung study results across the ongoing onartuzumab clinical programme.
Author: [email protected]
8-K – Current report
Lexicon has during 2013 initiated a companion study of telotristat etiprate in carcinoid syndrome (Filing 8K, Lexicon Pharmaceuticals, FEB 28, 2014, View Source [SID:1234500200]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
MEI Pharma Receives Orphan Status For Lead Drug Candidate Pracinostat For Treatment Of Acute Myeloid Leukemia
On February 28, 2014 MEI Pharma announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s investigational drug Pracinostat for the treatment of acute myeloid leukemia (AML) (Press release MEI Pharma, FEB 28, 2014, View Source [SID:1234500202]).
(Filing, 20-F, Theratechnologies, FEB 27, 2014, View Source [SID:1234504821])
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
20-F – Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
Theratechnologies has filed a 20-F – Annual and transition report of foreign private issuers [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Press release Theratechnologies, FEB 27, 2014, View Source [SID1234500172]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!